Literature DB >> 8633062

Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis.

C M Crews1, W S Lane, S L Schreiber.   

Abstract

The marine natural product didemnin B, currently in clinical trials as an antitumor agent, has several potent biological activities apparently mediated by distinct mechanisms. Our initial investigation of didemnin B resulted in the discovery of its GTP-dependent binding of the translation elongation factor EF1 alpha. This finding is consistent with the protein synthesis inhibitory activity of didemnin B observed at intermediate concentrations. To begin to dissect the mechanisms involved in the cytostatic and immunosuppressive activities of didemnin B, observed at low concentrations, additional didemnin-binding proteins were sought. Here we report the purification of a 36-kDa glycosylated didemnin-binding protein from bovine brain lysate. Cloning of the human cDNA encoding this protein revealed a strong sequence similarity with palmitoyl protein thioesterase (PPT), an enzyme that removes palmitate from H-Ras and the G alpha s subunits of heterotrimeric GTP-binding proteins in vitro. Mutations in PPT have recently been shown to be responsible for infantile neuronal ceroid lipofuscinosis, which is a severe brain disorder characterized by progressive loss of brain function and early death.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8633062      PMCID: PMC39533          DOI: 10.1073/pnas.93.9.4316

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase.

Authors:  J Chung; T C Grammer; K P Lemon; A Kazlauskas; J Blenis
Journal:  Nature       Date:  1994-07-07       Impact factor: 49.962

3.  Three-dimensional structure of the complex of the Rhizopus chinensis carboxyl proteinase and pepstatin at 2.5-A resolution.

Authors:  R Bott; E Subramanian; D R Davies
Journal:  Biochemistry       Date:  1982-12-21       Impact factor: 3.162

4.  A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) study.

Authors:  R B Weiss; B L Peterson; S L Allen; S M Browning; D B Duggan; C A Schiffer
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

5.  A microtiter plate assay for the characterization of serine proteases by their esterase activity.

Authors:  R G Whittaker; M K Manthey; D S Le Brocque; P J Hayes
Journal:  Anal Biochem       Date:  1994-08-01       Impact factor: 3.365

6.  Mode of inhibition of acid proteases by pepstatin.

Authors:  J Marciniszyn; J A Hartsuck; J Tang
Journal:  J Biol Chem       Date:  1976-11-25       Impact factor: 5.157

7.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

8.  Molecular cloning and expression of palmitoyl-protein thioesterase.

Authors:  L A Camp; L A Verkruyse; S J Afendis; C A Slaughter; S L Hofmann
Journal:  J Biol Chem       Date:  1994-09-16       Impact factor: 5.157

9.  Conformational flexibility in the active sites of aspartyl proteinases revealed by a pepstatin fragment binding to penicillopepsin.

Authors:  M N James; A Sielecki; F Salituro; D H Rich; T Hofmann
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

10.  Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis.

Authors:  J Vesa; E Hellsten; L A Verkruyse; L A Camp; J Rapola; P Santavuori; S L Hofmann; L Peltonen
Journal:  Nature       Date:  1995-08-17       Impact factor: 49.962

View more
  10 in total

1.  Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319).

Authors:  A Mittelman; H G Chun; C Puccio; N Coombe; T Lansen; T Ahmed
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  Total synthesis of Lys(3) tamandarin M: a potential affinity ligand.

Authors:  Kenneth M Lassen; Madeleine M Joullié
Journal:  Org Lett       Date:  2010-10-29       Impact factor: 6.005

Review 3.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

4.  Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B.

Authors:  Malia B Potts; Elizabeth A McMillan; Tracy I Rosales; Hyun Seok Kim; Yi-Hung Ou; Jason E Toombs; Rolf A Brekken; Mark D Minden; John B MacMillan; Michael A White
Journal:  Nat Chem Biol       Date:  2015-04-13       Impact factor: 15.040

5.  Consecutive interactions with HSP90 and eEF1A underlie a functional maturation and storage pathway of AID in the cytoplasm.

Authors:  Stephen P Methot; Ludivine C Litzler; Felipe Trajtenberg; Astrid Zahn; Francis Robert; Jerry Pelletier; Alejandro Buschiazzo; Brad G Magor; Javier M Di Noia
Journal:  J Exp Med       Date:  2015-03-30       Impact factor: 14.307

Review 6.  Natural Products Diversity of Marine Ascidians (Tunicates; Ascidiacea) and Successful Drugs in Clinical Development.

Authors:  Satheesh Kumar Palanisamy; N M Rajendran; Angela Marino
Journal:  Nat Prod Bioprospect       Date:  2017-01-17

7.  In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells.

Authors:  H Depenbrock; R Peter; G T Faircloth; I Manzanares; J Jimeno; A R Hanauske
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

8.  Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin.

Authors:  A Losada; J M López-Oliva; J M Sánchez-Puelles; L F García-Fernández
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

9.  Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex.

Authors:  Jordan D Carelli; Steven G Sethofer; Geoffrey A Smith; Howard R Miller; Jillian L Simard; William C Merrick; Rishi K Jain; Nathan T Ross; Jack Taunton
Journal:  Elife       Date:  2015-12-10       Impact factor: 8.140

10.  Antiangiogenic activity of aplidine, a new agent of marine origin.

Authors:  G Taraboletti; M Poli; R Dossi; L Manenti; P Borsotti; G T Faircloth; M Broggini; M D'Incalci; D Ribatti; R Giavazzi
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.